NEW CANAAN, CT--(Marketwire - June 26, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL), a clinical-stage biotechnology company developing a new class of oncology drugs known as “multi-signal transduction regulators,” today announced that it is soon to be included in the Russell 3000® Index, according to a preliminary list of additions recently posted on www.russell.com. Marshall Edwards, Inc.'s addition to the broad market Russell 3000® Index, which remains in place for one year, means automatic inclusion in the Russell 2000® Index. The 2008 reconstitution of the Russell indexes will take place after the market closes on June 27, 2008.
